Heiderscheit, Bryan C.
Blemker, Silvia S.
Opar, David
Stiffler-Joachim, Mikel R.
Bedi, Asheesh
Hart, Joseph
Mortensen, Brett
Kliethermes, Stephanie A.
Baer, Geoffrey
Buckley, Craig
Costigan, Kyle
Drew, Shauna
Eberhardt, Duffy
Fabian, Kurrel
Feller, Herman
Hammer, Erin
Heidt, Danielle
Lee, Kenneth
Lund, Brian
Martin, Jack
Moll, Michael
Sanfilippo, Jennifer
Snee, Shaun
Tanaka, Claire
Taylor, Ty
Wilson, John
Woodhouse, Devin
Lin, Yi-Chung
Hickey, Jack
Maniar, Nirav
Taylor, Frances
Timmins, Ryan
Cousins, Matthew
DuCharme, Olivia
Feng, Xue
Magargee, Scott
Meyer, Craig
Nguyen, Anthony
Riem, Lara
West, Robin
Allen, Steven
Allred, Dain
Beutler, Anthony
Bruening, Dustin
Campbell, Darren
Johnson, A. Wayne
Nguyen, Camille
Remington, Emma
Smedley, Annie A.
Sponbeck, Joshua K.
Berkoff, David
Berkowitz, Josh
Birchmeier, Thomas
Blackburn, Troy
Choudhari, Malvika
Ciocca, Mario
Lennon, Alessa
Lisee, Caroline
McCoy, Noah
Mincberg, David
Oliaro, Scott
Pietrosimone, Brian
Ross, Luke
Titter, Julie
Sund, Sarah
,
Funding for this research was provided by:
NFL Foundation (AAJ5998 MSN249213)
Article History
Received: 18 May 2022
Accepted: 6 July 2022
First Online: 15 July 2022
Change Date: 19 July 2022
Change Type: Update
Change Details: The HAMIR Study Group names have been added to the PDF version of this article.
Declarations
:
: This study is approved by the Institutional Review Boards of the University of Wisconsin-Madison (Protocol ID: 2021-1420), Brigham Young University (Protocol ID: 2021-395), and University of North Carolina-Chapel Hill (Protocol ID: 21-3293). Written informed consent is obtained from all participants before inclusion. The research is performed according to the Association for the Accreditation of Human Research Protection Programs (AAHRPP) guidelines.
: Not applicable.
: Bryan Heiderscheit is a paid consultant to Biocore, has ownership interest in Science of Running Medicine LLC, is an advisory board member for Springbok Analytics (stock options) and has received research funding from the National Basketball Association and GE Healthcare. David Opar is listed as a co-inventor on a patent, filed by the Queensland University of Technology (QUT), for a field-testing device of eccentric hamstring strength, which is now known commercially as the NordBord. Dr Opar has received revenue distributions from QUT based on revenue that QUT has generated through the commercialization of his intellectual property. Dr Opar is a minority shareholder in Vald Performance Pty Ltd, the company responsible for commercialization of the NordBord, among other devices. Dr Opar has received research funding from Vald Performance, for work unrelated to the current manuscript. Dr Opar is also the Chair of the Vald Performance Research Committee, a role that is unpaid. Dr Opar has family members who are minor shareholders and/or employees of Vald Performance. Silvia Blemker is co-founder and Chief Scientific Officer of Springbok Analytics and has shares in the company. Asheesh Bedi is an advisory board member for Springbok Analytics (stock options) and ViewFi (shares), and receives consulting fees and royalties from Arthrex. Joseph Hart is co-founder and Scientific Advisor of Springbok Analytics. Lara Riem is employed by Springbok Analytics and has stock options. Xue Feng is the Chief Technology Officer for Springbok Analytics and has shares in the company. Matthew Cousins is employed by Springbok Analytics. Olivia DuCharme is employed by Springbok Analytics. Anthony Nguyen is employed by Springbok Analytics. Geoff Baer has received consulting fees from Conmed. Kenneth Lee has received research and grant support from the National Basketball Association, GE Healthcare and Supersonic Imagine, and receives royalties from Elsevier. John Wilson has received research and grant support from GE Healthcare and Depuy Synthes. The remaining authors declare that they have no competing interests.